Co-delivery of autoantigen and b7 pathway modulators suppresses experimental autoimmune encephalomyelitis

AAPS Journal

Volumn 16, Issue 6, 2014, Pages 1204-1213

  Northrup, Laura ^a   Sestak, Joshua O ^a   Sullivan, Bradley P ^a   Thati, Sharadvi ^a   Hartwell, Brittany L ^b   Siahaan, Teruna J ^a   Vines, Charlotte M ^c   Berkland, Cory ^a,b  

^a UNIVERSITY OF KANSAS   (United States)

^b University of Kansas   (United States)

^c UNIVERSITY OF TEXAS AT EL PASO   (United States)

Author keywords

Antigen specific immunotherapy; B7 CD28:CTLA 4 co stimulatory pathway; Experimental autoimmune encephalomyelitis (EAE); Proteolipid peptide; Soluble antigen array

Indexed keywords

B7 BINDING PEPTIDE; BINDING PROTEIN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; PROTEIN INHIBITOR; SOLUBLE ANTIGEN ARRAY; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; AUTOANTIGEN; B7 ANTIGEN; CYTOKINE; DRUG CARRIER; HYALURONIC ACID; MYELIN PROTEOLIPID PROTEIN (139-151); PEPTIDE; PEPTIDE FRAGMENT; PLP-BPI PEPTIDE; PROTEOLIPID PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SYNTHESIS; EX VIVO STUDY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; GEL PERMEATION CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMAGING AND DISPLAY; IMMUNE RESPONSE; IMMUNOTHERAPY; MICROFLOW IMAGING; MOUSE; MULTIPLE SCLEROSIS; MURINE MODEL; NONHUMAN; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; SPLEEN CELL; SYMPTOM; ANIMAL; BIOSYNTHESIS; CELL CULTURE; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; INBRED MOUSE STRAIN; SOLUBILITY; SPLEEN;

ANIMALS; AUTOANTIGENS; B7 ANTIGENS; CELLS, CULTURED; CYTOKINES; DRUG CARRIERS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; HYALURONIC ACID; IMMUNE TOLERANCE; MICE, INBRED STRAINS; MYELIN PROTEOLIPID PROTEIN; PEPTIDE FRAGMENTS; PEPTIDES; SOLUBILITY; SPLEEN;

EID: 84938810997     PISSN: None     EISSN: 15507416     Source Type: Journal    
DOI: 10.1208/s12248-014-9671-y     Document Type: Article

References (44)

1. Fletcher JM, Lalor SJ, Sweeney CM, Tubridy N, Mills KH. T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Clin Exp Immunol. 2010;162(1):1–11.
2. Ransohoff RM, Brown MA. Innate immunity in the nervous system. J Clin Invest. 2012;122(4):1164–71.
3. Amor S, Puentes F, Baker D, Van Der Valk P. Inflammation in neurodegenerative diseases. Immunology. 2010;129(2):154–69.
4. Feldmann M, Steinman L. Design of effective immunotherapy for human autoimmunity. Nature. 2005;435(7042):612–9.
5. Bates D. Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials. Neurology. 2011;76:S14–25.
6. Miller SD, Turley DM, Podojil JR. Antigen-specific tolerance strategies for the prevention and treatment of autoimmune disease. Nat Rev Immunol. 2007;7(9):665–77.
7. Langer-Gould A, Steinman L. Progressive multifocal leukoencephalopathy and multiple sclerosis: lessons from natalizumab. Curr Neurol Neurosci Rep. 2006;6(3):253–8.
8. Kindt TJ, Goldsby RA, Osborne BA, Kuby J. Kuby immunology. 6th ed. New York: W.H. Freeman and Company; 2007.
9. Gonsette RE. Self-tolerance in multiple sclerosis. Acta Neurol Belg. 2012;112(2):133–40.
10. Barnett MH, Sutton I. The pathology of multiple sclerosis: a paradigm shift. Curr Opin Neurol. 2006;19(3):242–7.
11. Bromley SK, Iaboni A, Davis SJ, Whitty A, Green JM, Shaw AS, et al. The immunological synapse and CD28-CD80 interactions. Nat Immunol. 2001;2(12):1159–66.
12. Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat Rev Immunol. 2002;2(2):116–26.
13. Chittasupho C, Siahaan TJ, Vines CM, Berkland C. Autoimmune therapies targeting costimulation and emerging trends in multivalent therapeutics. Ther Deliv. 2011;2(7):873–89.
14. Badawi AH, Siahaan TJ. Immune modulating peptides for the treatment and suppression of multiple sclerosis. Clin Immunol. 2012;144(2):127–38.
15. Chittasupho C, Sestak J, Shannon L, Siahaan TJ, Vines CM, Berkland C. Hyaluronic acid graft polymers displaying peptide antigen modulate dendritic cell response in vitro. Mol Pharm. 2013;11(1):367–73. doi: 10.1021/mp4003909.
16. Sabatos-Peyton CA, Verhagen J, Wraith DC. Antigen-specific immunotherapy of autoimmune and allergic diseases. Curr Opin Immunol. 2010;22(5):609–15.
17. Yao S, Zhu Y, Chen L. Advances in targeting cell surface signalling molecules for immune modulation. Nat Rev Drug Discov. 2013;12(2):130–46.
18. Chen J, He Q, Zhang R, Chu Y, Wang Y, Liu Q, et al. Allogenic donor splenocytes pretreated with antisense peptide against B7 prolong cardiac allograft survival. Clin Exp Immunol. 2004;138(2):245–50.
19. Srinivasan M, Lu D, Eri R, Brand DD, Haque A, Blum JS. CD80 binding polyproline helical peptide inhibits T cell activation. J Biol Chem. 2005;280(11):10149–55.
20. Dudhgaonkar SP, Janardhanam SB, Kodumudi KN, Srinivasan M. CD80 blockade enhance glucocorticoid-induced leucine zipper expression and suppress experimental autoimmune encephalomyelitis. J Immunol. 2009;183(11):7505–13.
21. Srinivasan M, Gienapp IE, Stuckman SS, Rogers CJ, Jewell SD, Kaumaya PT, et al. Suppression of experimental autoimmune encephalomyelitis using peptide mimics of CD28. J Immunol. 2002;169(4):2180–8.
22. Kobayashi N, Kobayashi H, Gu L, Malefyt T, Siahaan TJ. Antigen-specific suppression of experimental autoimmune encephalomyelitis by a novel bifunctional peptide inhibitor. J Pharmacol Exp Ther. 2007;322(2):879–86.
23. Murray JS, Oney S, Page JE, Kratochvil-Stava A, Hu Y, Makagiansar IT, et al. Suppression of type 1 diabetes in NOD mice by bifunctional peptide inhibitor: modulation of the immunological synapse formation. Chem Biol Drug Des. 2007;70(3):227–36.
24. Sestak J, Mullins M, Northrup L, Thati S, Forrest ML, Siahaan TJ, et al. Single-step grafting of aminooxy-peptides to hyaluronan: a simple approach to multifunctional therapeutics for experimental autoimmune encephalomyelitis. J Control Release. 2013;168(3):334–40.
25. Sestak JO, Sullivan BP, Thati S, Northrup L, Hartwell B, Antunez L, et al. Codelivery of antigen and an immune cell adhesion inhibitor is necessary for efficacy of soluble antigen arrays in experimental autoimmune encephalomyelitis. Mol Ther Methods Clin Dev. 2014. doi:10.1038/mtm.2014.8.
26. Manikwar P, Kiptoo P, Badawi AH, Büyüktimkin B, Siahaan TJ. Antigen-specific blocking of CD4-Specific immunological synapse formation using BPI and current therapies for autoimmune diseases. Med Res Rev. 2012;32(4):727–64.
27. Badawi AH, Kiptoo P, Wang W-T, Choi I-Y, Lee P, Vines CM, et al. Suppression of EAE and prevention of blood–brain barrier breakdown after vaccination with novel bifunctional peptide inhibitor. Neuropharmacology. 2012;62(4):1874–81.
28. Ridwan R, Kiptoo P, Kobayashi N, Weir S, Hughes M, Williams T, et al. Antigen-specific suppression of experimental autoimmune encephalomyelitis by a novel bifunctional peptide inhibitor: structure optimization and pharmacokinetics. J Pharmacol Exp Ther. 2010;332(3):1136–45.
29. Constantinescu CS, Farooqi N, O’Brien K, Gran B. Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). Br J Pharmacol. 2011;164(4):1079–106.
30. Yao YF, Zhou YM, Xiang JB, Gu XD, Cai D. Inhibition of arterial allograft intimal hyperplasia using recipient dendritic cells pretreated with B7 antisense peptide. Clin Dev Immunol. 2012;2012:892687.
31. Fukumoto T, Torigoe N, Kawabata S, Murakami M, Uede T, Nishi T, et al. Peptide mimics of the CTLA4-binding domain stimulate T-cell proliferation. Nat Biotechnol. 1998;16(3):267–70.
32. Lutterotti A, Yousef S, Sputtek A, Sturner KH, Stellmann JP, Breiden P, et al. Antigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosis. Sci Transl Med. 2013;5(188):188ra75.
33. Bar-Or A, Vollmer T, Antel J, Arnold DL, Bodner CA, Campagnolo D, et al. Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial. Arch Neurol. 2007;64(10):1407–15.
34. Kang Y, Xu L, Wang B, Chen A, Zheng G. Cutting edge: immunosuppressant as adjuvant for tolerogenic immunization. J Immunol. 2008;180(8):5172–6.
35. Kang Y, Zhao J, Liu Y, Chen A, Zheng G, Yu Y, et al. FK506 as an adjuvant of tolerogenic DNA vaccination for the prevention of experimental autoimmune encephalomyelitis. J Gene Med. 2009;11(11):1064–70.
36. Cousens LP, Su Y, McClaine E, Li X, Terry F, Smith R, et al. Application of IgG-derived natural Treg epitopes (IgG Tregitopes) to antigen-specific tolerance induction in a murine model of type 1 diabetes. J Diabetes Res. 2013;2013:621693.
37. Eri R, Kodumudi KN, Summerlin DJ, Srinivasan M. Suppression of colon inflammation by CD80 blockade: evaluation in two murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(4):458–70.
38. Deppong CM, Bricker TL, Rannals BD, Van Rooijen N, Hsieh CS, Green JM. CTLA4Ig inhibits effector T cells through regulatory T cells and TGF-beta. J Immunol. 2013;191(6):3082–9.
39. Ward FJ, Dahal LN, Wijesekera SK, Abdul-Jawad SK, Kaewarpai T, Xu H, et al. The soluble isoform of CTLA-4 as a regulator of T-cell responses. Eur J Immunol. 2013;43(5):1274–85.
40. Yamamoto T, Hattori M, Yoshida T. Induction of T-cell activation or anergy determined by the combination of intensity and duration of T-cell receptor stimulation, and sequential induction in an individual cell. Immunology. 2007;121(3):383–91.
41. Petitto JM, Streit WJ, Huang Z, Butfiloski E, Schiffenbauer J. Interleukin-2 gene deletion produces a robust reduction in susceptibility to experimental autoimmune encephalomyelitis in C57BL/6 mice. Neurosci Lett. 2000;285(1):66–70.
42. Rodgers JM, Miller SD. Cytokine control of inflammation and repair in the pathology of multiple sclerosis. Yale J Biol Med. 2012;85(4):447–68.
43. Lambrecht BN, Kool M, Willart MA, Hammad H. Mechanism of action of clinically approved adjuvants. Curr Opin Immunol. 2009;21(1):23–9.
44. Peek LJ, Middaugh CR, Berkland C. Nanotechnology in vaccine delivery. Adv Drug Deliv Rev. 2008;60(8):915–28.